When mouse 30A5 preadipocytes are exposed to high glucose concentrations, acetyl-CoA carboxylase is induced through glucose activation of promoter II of the acetyl-CoA carboxylase gene. Glucose treatment of the cells increases Sp1 binding to two GC-rich glucose response elements in promoter II. We have investigated the mechanism by which glucose increases Sp1 binding and transactivation of promoter II in 30A5 cells. DNA mobility shift assays have shown that nuclear extracts from glucose-treated cells exhibit increased Sp1 binding activity. This increase in the binding activity is not due to glucose-mediated changes in the amount of Sp1 in the nucleus but to an increase in the activity that modifies Sp1 so that it binds more effectively to the promoter sequence. This Sp1 modifying activity is inhibited by okadaic acid and phosphatase inhibitor 2, and has a molecular mass of 38 -42 kDa. The catalytic subunit of type 1 protein phosphatase, whose molecular mass is 38 kDa, also increased the ability of Sp1 to bind to promoter II. Treatment of nuclear extract with antibodies against the catalytic subunit partially suppressed the nuclear activity for Sp1 activation. From these results, we conclude that the Sp1 transcription factor exhibits enhanced binding to promoter II and transcriptional activation is the result of glucose-induced dephosphorylation by type 1 phosphatase.
When mouse 30A5 preadipocytes are exposed to high glucose concentrations, acetyl-CoA carboxylase is induced through glucose activation of promoter II of the acetyl-CoA carboxylase gene. Glucose treatment of the cells increases Sp1 binding to two GC-rich glucose response elements in promoter II. We have investigated the mechanism by which glucose increases Sp1 binding and transactivation of promoter II in 30A5 cells. DNA mobility shift assays have shown that nuclear extracts from glucose-treated cells exhibit increased Sp1 binding activity. This increase in the binding activity is not due to glucose-mediated changes in the amount of Sp1 in the nucleus but to an increase in the activity that modifies Sp1 so that it binds more effectively to the promoter sequence. This Sp1 modifying activity is inhibited by okadaic acid and phosphatase inhibitor 2, and has a molecular mass of 38 -42 kDa. The catalytic subunit of type 1 protein phosphatase, whose molecular mass is 38 kDa, also increased the ability of Sp1 to bind to promoter II. Treatment of nuclear extract with antibodies against the catalytic subunit partially suppressed the nuclear activity for Sp1 activation. From these results, we conclude that the Sp1 transcription factor exhibits enhanced binding to promoter II and transcriptional activation is the result of glucose-induced dephosphorylation by type 1 phosphatase.
Long-chain fatty acids are structural components of the cell as well as its main energy reserves. They also play an important role in various cellular and regulatory functions (1) (2) (3) (4) (5) . Glucose serves as the primary precursor of these long-chain fatty acids in the lipogenic tissues of eukaryotes. A number of key enzymes in glycolysis and lipogenesis, including acetylCoA carboxylase (ACC), 1 are activated by glucose at the transcriptional level (6, 7) . ACC catalyzes the rate-limiting reaction in the synthesis of long-chain fatty acids, and its gene is under the control of two promoters: promoter I (PI) and II (PII) (8, 9) . We have previously shown that only promoter II of the ACC gene is activated by high concentrations of glucose (10) . This effect of glucose requires the two GC-rich sequences that are located between Ϫ340 and Ϫ249 of PII; occupancy of both sites by Sp1 was found to be essential for the glucose induction of PII activity. Glucose treatment of the cells caused increased binding of Sp1 to these sites.
In this report, we show that the glucose-mediated increased binding of Sp1 to DNA is due to the dephosphorylation of the existing Sp1 in the nucleus. Glucose induces this dephosphorylation activity in the nucleus. Glucose treatment increases the amount of the catalytic subunit (CS1) of phosphoprotein phosphatase 1 (PP1), which may result in activation of Sp1 binding activity. This would, therefore, be the first example of dephosphorylation of Sp1 by PP1 in promoting transcriptional activation of a gene. Cell Culture and CAT Assay-Mouse 30A5 preadipocytes were cultured in 100-mm Petri dishes to about 90% confluence in Eagle's basal medium supplemented with 10% donor calf serum. The glucose treatment was as follows: cells that had just reached confluence were treated with dexamethasone (1.0 mM) and isobutylmethylxanthine (0.5 mM) in a glucose-deficient RPMI 1640 medium that was supplemented with either 10 mM lactate or 27.5 mM glucose. After 48 h the medium was removed and the cells were washed with phosphate-buffered saline. They were again incubated with either 10 mM lactate or 27.5 mM glucose in RPMI 1640 medium for another 48 h. At the end of the above treatment, cells were harvested and assayed for CAT activity.
EXPERIMENTAL PROCEDURES

Materials--Commercial
Preparation of Nuclear Extracts-Nuclear extracts were prepared according to the method described by Dignam et al. (11) . 30A5 cells were subjected to the treatment described above and nuclear extracts were prepared from the control cells, i.e. lactate-treated cells, and from the glucose-treated cells. They were then divided into aliquots and stored at Ϫ80°C. Two to three mg of protein was obtained from 10 8 cells. Mobility Shift DNA Binding Assay-The following oligonucleotide was used in the gel retardation assays: E-50 mer:5Ј-CGGAGGA-CCATCGGCATTCGCTCACGTCGCCCCGCCCCGCGCCGGGAGCT-3Ј. Double-stranded oligonucleotides were prepared by combining equal amounts of the complementary single-stranded DNA in a solution containing 10 mM MgCl 2 , heating to 80°C for 5 min, and then slowly cooling to room temperature. The annealed oligonucleotides were endlabeled with [␥-32 P]ATP and T4 DNA polynucleotide kinase. Binding reactions were carried out in 20 l containing 10 mM HEPES, pH 7.9, 75 mM KCl, 1 mM EDTA, 5 mM dithiothreitol, 5 mM MgCl 2 , 10% glycerol, 1 g of poly(dI-dC). A typical reaction contained 20,000 cpm (0.5-1 ng) of end-labeled DNA with 2-5 g of nuclear extract. The reaction mixture was incubated on ice for 30 min and then loaded onto a 5% nondena-turing polyacrylamide gel. Electrophoresis was carried out at 100 V for approximately 4 h in 25 mM Tris, 190 mM glycine, and 1 mM EDTA, pH 8.5. The gel was then fixed in 10% methanol, 10% acetic acid, dried, and autoradiographed.
Western Blot Analysis and Immunodepletion Studies-Western immunoblot analysis was performed using the procedure of Tae et al. (12) . Sp1 was detected using rabbit polyclonal antibodies against a synthetic peptide corresponding to amino acid residues 520 -538 of the Sp1 protein and analyzed by 10% SDS-PAGE. In the immunodepletion studies, nuclear extracts from 30A5 cells were treated with 2-10 g of anti-CS1 polyclonal antibodies or control serum for 4 -5 h. After incubation with 50 l of protein A-Sepharose beads for 2 h with constant shaking, the samples were centrifuged for 5 min at 14,000 ϫ g. Equal volumes of non-and antibody-depleted supernatants were then used in the mobility shift assays.
Renaturation of Proteins Separated by SDS-PAGE-Forty micrograms of nuclear extract from glucose-treated 30A5 cells was subjected to electrophoresis in an 11% SDS-polyacrylamide gel. The gel was transversely sliced 2 mm in width. Each gel slice was placed into a 1.5-ml Eppendorf tube containing three volumes of the slice weight of elution-renaturation buffer. This buffer contained 1% Triton X-100, 20 mM Hepes, pH 7.6, 1 mM EDTA, 100 mM NaCl, 4 mg/ml bovine serum albumin, 2 mM dithiothreitol, 0.1 mM phenylmethylsulfonyl fluoride, and 0.1% Trasylol. After homogenizing the gel slices with a small Teflon stainless steel pestle, the mixture was incubated at 37°C for 4 h. After centrifugation of the samples for 10 min at 14,000 ϫ g, the supernatant (ϳ60% of the total volume) was transferred to a new tube and 5 l of each fraction was incubated with 5 ng of purified Sp1 for the mobility shift assay.
RESULTS
Effect of Glucose on Sp1
Binding to PII-We have previously localized the glucose-responsive elements to the two GC boxes that are in a 91-base pair region between Ϫ340 and Ϫ249 of PII of the ACC gene (10) . The transcription factor Sp1 binds to these GC boxes, and glucose treatment increases binding of Sp1 at these sites ( Fig. 1 ). As indicated in Fig. 1 , glucose treatment shows an increase in Sp1 binding activity. When a 50-base pair oligonucleotide from bases Ϫ282 to Ϫ233, containing one of the two glucose response elements of PII, was incubated with 30A5 nuclear extract, three complexes (B1, B2, and B3) were formed (Fig. 1, lanes 2 and 3) . Glucose treatment of the cells increased the binding activities of all three bands (Fig.  1 , lane 3 versus lane 2). B1 and B2 were previously identified as Sp3 and Sp1, respectively. Using Schneider cells, which lack the Sp1 transcription factor, we showed previously that Sp1 alone can activate PII expression (10) . We have no information as to Sp3 and the other factor responsible for B3 in the glucosemediated PII activation, except that B1 and B3 are also increased by glucose treatment.
In order to examine if glucose-mediated increases in the DNA-protein complex are due to an increase in the amount of Sp1, or to the activation of existing Sp1, Western blot analyses of nuclear extracts from glucose-treated and control cells were carried out. The amount of Sp1 did not change as a result of glucose treatment of the cells (data not shown). Hence, an increase in Sp1 binding is not due to an increase in the quantity of Sp1 in the nucleus. There are several examples of phosphorylation either stimulating or inhibiting the ability of a transcription factor to bind to DNA (13). Jackson et al. initially reported that Sp1 is a phosphoprotein and the phosphorylation of Sp1 both in vitro and in vivo is dependent on its binding to the DNA recognition element (14) .
Glucose Induces a Nuclear Factor That Enhances Sp1 Binding to PII-In an attempt to determine the mechanism of the glucose-mediated increase in Sp1 binding to PII, we examined the effect of nuclear extracts from glucose-treated cells on purified Sp1 with regard to its binding to PII ( Fig. 2A) . When a small amount of nuclear extract (1 g of nuclear protein) was used in a DNA mobility shift assay, very weak band retardation was observed (Fig. 2A, lane 2) . However, the addition of 5 ng of purified Sp1 enhanced this binding activity severalfold ( Fig.  2A, lane 4) , although the same amount of Sp1 alone was unable to bind to DNA (Fig. 2A, lane 6 ). This observation suggested the presence of an Sp1 modifying activity in the nuclear extract that increases its ability to bind to PII. Fig. 2A also shows the results of supershift studies employing Sp1-specific antibodies ( Fig. 2A, lanes 3, 5, and 7) . Lanes 3 and 5 show the presence of a higher molecular weight species, formed by the reaction of Sp1 with its antibody and indicates that the enhanced binding is due to more Sp1 in the DNA-protein complex. To examine the effect of glucose treatment of the cells on this Sp1 modifying activity, we compared the activities in nuclear extracts from both control and glucose-treated cells. While the enhanced binding activity of Sp1 in the presence of nuclear extract from the control cells decreased upon a 4-fold dilution of the nuclear extract (Fig. 2B, lanes 2, 4, and 6) , the binding activity of Sp1 for the same concentration of nuclear extract from glucosetreated cells increased 4-fold (Fig. 2B, lanes 8, 10, and 12 ). This level of increase in the nuclear activity in the activation of the Sp1 binding corresponds to the increased amount in CS1, as will be seen in Fig. 7 . Thus, it is clear that glucose treatment induces a nuclear factor that enhances Sp1 binding to the promoter.
Size Determination of the Factor That Enhances Sp1 Binding to PII-To obtain further information on the nature of the factor responsible for the glucose-mediated activation of Sp1 binding activity to PII, nuclear extracts from glucose-treated cells were subjected to SDS-PAGE and the gel was sliced into pieces containing a 2-4-kDa difference in protein sizes. Gel mobility shift assays were carried out with the renatured proteins from each fraction in the presence of 5 ng of purified Sp1. As shown in Fig. 3 , only fraction number 6, with 38 -42-kDa proteins, contained an activity that was able to increase the binding of Sp1 to the glucose-responsive element of PII. 30A5 Cells-Previously we showed that glucose activation of ACC in INS-1 ␤-pancreatic cells involved the dephosphorylation of ACC by a protein phosphatase (15) . To determine if the modification of Sp1 involved a phosphatase activity, the effect of okadaic acid (OA), a potent phosphatase inhibitor, was examined on the nuclear activity in the modification of Sp1. As shown in Fig. 4 , increasing concentrations of OA progressively decreased the enhanced DNA binding ability of Sp1 by nuclear extract (Fig. 4, lanes 3-5 versus lane 2) . Lane 1 represents nuclear extract alone. Thus, OA inhibition of the nuclear activity was at an IC 50 (concentration required for 50% inhibition) of 25 nM, which is close to the IC 50 of PP1 (16, 17) .
Effect of Okadaic Acid on the Nuclear Factor Responsible for Sp1 Modification and Glucose-mediated Activation of PII in
Treatment with 200 nM OA removed over 90% of the nuclear activity, which is presumably a protein phosphatase 1 activity. To show that the same nuclear activity for Sp1 is also involved in the activation of PII by glucose, 30A5 cells that are stably transfected with pPII-CAT3 were used to examine the effect of OA on glucose activation of CAT gene expression (Fig. 5) . pPII-CAT3 contains the two Sp1 sites responsible for the glucose activation of PII (10) . As a control, OA was added alone to one set of plates and glucose was added to another set. The cells were harvested after 48 h and CAT activity was determined. As   FIG. 2 . DNA mobility shift and supershift assays with 30A5 nuclear extract. A, the E-50-mer (Ϫ282 to Ϫ233) of PII was endlabeled and incubated with 1 g of nuclear extract from 30A5 cells (lanes 2 and 3) or with 1 g of nuclear extract and 5 ng of purified Sp1 (lanes 4 and 5) . Lanes 6 and 7 denote Sp1 alone. 1-2 l of anti-Sp1 was added to lanes 3, 5, and 7. Lane 1 shows the position of the labeled DNA or free probe. The labeled DNA was added to the reaction mixture after the antibody reaction. B, serially diluted nuclear extract, i.e. 2.0 g in lanes 1 and 2, 1.0 g in lanes 3 and 4, 0.5 g in lanes 5 and 6, 0.25 g in lanes 7 and 8, and 0.125 g in lanes 9 and 10, was incubated with (lanes 2, 4, 6, 8, 10, and 12) and without (lanes 1, 3, 5, 7, 9 , and 11) 5 ng of Sp1 in the binding mixture with the E-50-mer as the labeled probe.
FIG. 3.
Size determination of the factor that enhances Sp1 binding to PII. Forty micrograms of nuclear extract from glucosetreated 30A5 cells were separated by an 11% SDS-polyacrylamide gel. The gel was transversely sliced into fractions of 2-4 kDa. Each gel slice was placed into a 1.5-ml Eppendorf tube containing 3 (v/w) of elution buffer. The samples were renatured, and 5 l of each fraction was incubated with 5 ng of purified Sp1 and used in the mobility shift assay with the E-50-mer as the labeled probe. Lanes 1-11 represent the different size fractions.
FIG. 4. DNA mobility shift assays with OA.
To study the effect of OA on nuclear extract and Sp1, mobility shift assays were performed without (lanes 1 and 2) and with (lanes 3-6) 25, 50, 100, and 200 nM OA, respectively. Lane 1 contains 1 g of nuclear extract from 30A5 cells, while lanes 2-6 have nuclear extract plus 5 ng of purified Sp1. The probe used in the binding reaction is the end-labeled E-50-mer.
shown in Fig. 5 , the addition of OA completely inhibited glucose activation of PII, while OA alone had little effect on CAT gene expression.
Protein Phosphatase 1 (PP1) Enhances Sp1
Binding to PIITwo observations led us to examine the effect of protein PP1 on Sp1 binding to PII (Fig. 6 ). 1) The size of the nuclear factor that enhances Sp1 binding to PII is about 38 -42 kDa, the size of the catalytic subunit of PP1; and 2) glucose-mediated activation of Sp1 binding to PII is OA-sensitive at a concentration suggesting the factor to be a PP1-like activity. In the presence of 5 ng of Sp1, no binding activity was observed. When Sp1 was treated with 80 ng of recombinant CS1␣, the treated Sp1 bound to the DNA in a defined and enhanced manner at the position of the complex formed with nuclear extract and Sp1 (Fig. 6A, lane 4  versus lane 3) . Purified Sp1 exists in both the phosphorylated and dephosphorylated forms. When low concentrations of Sp1 are used, as in the above case, the amount of the dephosphorylated form of Sp1 is not enough to exhibit strong binding to the promoter sequence and Sp1 tends to aggregate to give rise to a complex of lower mobility. Furthermore, OA effectively suppressed the phosphatase 1 induced Sp1 binding to the B-50-mer (Fig. 6A, lane 6 versus lane 4) . No effect on binding activity was seen when OA was added to Sp1 alone (Fig. 6A, lane 5) .
In order to determine if the activation of Sp1 binding to promoter II is PP1-specific, DNA mobility shift assays were carried out using inhibitor 2 (I-2) (18). As shown in Fig. 6B , inhibitor 2 decreased the enhanced DNA binding ability of Sp1 by nuclear extract (Fig. 6B, lane 4 versus lane 3) . Lanes 1 and 2 represent DNA binding assays carried out with purified Sp1 and 30A5 nuclear extract, respectively. A similar inhibition was observed in the activation of Sp1 binding to the DNA by PP1 (Fig. 6B, lane 7 versus lane 6) . Lane 5 represents PP1 alone, while in lane 8 labeled DNA served as the free probe.
Effect of Glucose on the Level of CS1 in Nuclear Extracts-In order to determine if glucose treatment had any effect on the amount of phosphatase 1 in 30A5 cells, we performed an SDS-PAGE with the control and glucose-treated nuclear extracts. As shown in Fig. 7 , when the blot was incubated with anti-CS1 antibody, both the control and glucose-treated nuclear extracts cross-reacted with a specific CS1 antibody (lanes 1 and 2,  respectively) . More importantly, higher amounts of CS1 were observed with the glucose-treated nuclear extracts. It thus appears that the increase in Sp1 binding efficiency is caused by glucose induction of PP1, or a PP1-like activity. FIG. 5 . CAT activity assays with okadaic acid. Stable clones of the promoter II-CAT chimeric gene construct pPII-CAT3, which contains the two glucose response elements, were grown to the D2 stage of differentiation as described under "Experimental Procedures." Lactate, glucose, OA, or glucose plus OA were then given to the cells for 48 h after which they were harvested and CAT activity determined. The y axis corresponds to the relative CAT activity data obtained for each of these constructs. Each value represents the mean Ϯ standard deviation calculated from three experiments.
FIG. 6.
A, DNA mobility shift assays with phosphatase 1. The mobility shift assays were performed using labeled E-50-mer as the probe. Lanes 1 and 2 have added 30A5 cell nuclear extract (1 g), while lane 2 has 5 ng of added Sp1 as well. Lane 3 has 5 ng of purified Sp1 alone. To study the effect of protein phosphatase 1, DNA mobility shift assays were carried out using 80 ng of recombinant CS1␣ in lanes 4 and 6. In addition, the phosphatase inhibitor, okadaic acid was used in lanes 5 and 6. B, DNA mobility shift assays with inhibitor 2 (I-2). The DNA mobility shift assays were performed using labeled E-50-mer as the probe. Lanes 1 and 2 have purified Sp1 (5 g) and 30A5 cell nuclear extract (0.1 g), respectively. In lanes 3 and 4, 5 ng of purified Sp1 was used along with the nuclear extract in the binding assay. To study the effect of inhibitor 2 on the nuclear activation of Sp1 binding to promoter 2, DNA mobility shift assays were carried out using 50 nM of recombinant inhibitor 2 as shown in lane 4. Lane 5 has CS1␣ (80 ng) alone. In lanes 6 and 7, 5 ng of Sp1 was incubated with CS1␣ in the reaction mixture. To study the effect of inhibitor 2 on the CS1␣ activation of Sp1 binding to promoter 2, 50 nM of inhibitor 2 was used in lane 7. Lane 8 has labeled DNA as the free probe.
Effect of the Anti-CS1 Immunodepleted Nuclear Extracts on Sp1
Binding to PII-To confirm further that dephosphorylation of Sp1 by PP1 is involved in the glucose-mediated activation of PII, the nuclear extract was incubated first with anti-CS1 or anti-CS1 and PP2A antibody, and the effect of removing phosphatase from the nuclear extract on Sp1 binding activity was examined. Mobility shift assays were carried out using the supernatant of nontreated (Fig. 8, lanes 2 and 3) , PP1 antibody-depleted (Fig. 8, lanes 4 and 5) , and PP1 and PP2A antibody-depleted nuclear extracts (Fig. 8, lanes 6 and 7) . Treatment with an antibody against PP1 decreased the ability to enhance Sp1 binding activity. However, we were unable to completely remove Sp1 binding activity, even when the concentration of added anti-CS1 was increased severalfold. This can probably be explained by the fact that dephosphorylation of Sp1 can still be mediated by other isoforms of CS1, or the addition of purified Sp1, which exists in both the phosphorylated and dephosphorylated forms (50:50), masks the effect of the removal of PP1. We also observed (Fig. 8, lanes 6 and 7) , that immunodepletion of PP2A after removal of PP1 apparently increased the ability of Sp1 to bind to DNA. It is possible that PP2A functions in a manner different from that of PP1 and would form an interesting topic of study in the future.
DISCUSSION
Glucose activation of the ACC gene has been shown previously to be at the transcriptional level (7, 10) . Induction of ACC gene expression in response to glucose is mediated through its promoter II. Promoter II has no CCAAT or TATA box and has the structural features of a housekeeping gene. Even though PII is constitutively expressed in all cells, ACC gene products increase under lipogenic conditions such as the presence of high glucose concentrations in the cell.
The region of promoter II responsible for conferring glucosestimulated transcription activation contains two GC boxes, which are the consensus binding sites of the nuclear factor Sp1. Sp1 binds to these sequences and activates transcription from PII (10) . Regulation of transcription activation by Sp1 is mediated through its recognition sequence, the GGGCGG hexanucleotide, which functions in an orientation-independent manner (19 -22) . Studies with the herpes simplex virus-thymidine kinase, dihydrofolate reductase, and SV40 promoters, however, have shown that this core sequence does not necessarily imply a strong Sp1-binding site, and that the flanking sequence to the GC box is important in imparting varying binding affinities to Sp1 toward its recognition site. In addition to the sequence-specific binding to DNA, changes in DNA conformation induced by Sp1 binding at multiple sites in promoters, to form looped DNA structures, appear to be one mechanism in the transactivation by Sp1 (23) (24) (25) . Another striking feature of this factor is its ability to activate transcription synergistically with other heterologous activators. For example, the direct binding interaction between Sp1 and the bovine papilloma virus enhancer E2 protein to activate transcription from a papilloma viral promoter is observed even in the absence of an E2 DNA-binding motif (26) . On the other hand, certain nuclear factors like the retinoblastoma protein, a tumor-suppressor protein, have been implicated in augmenting Sp1-mediated transcription either by liberating Sp1 from a negative regulator or by facilitating the interaction of Sp1 with the components of the basal transcription complex (27, 28) . These varied mechanisms of Sp1-mediated transactivation appear to be promoter-specific and in response to specific extracellular signals. They could be affected either through a change in the absolute quantity of Sp1 molecules in the cell or by the posttranslational modification of the transcription factor. Other factors homologous to Sp1 have also been cloned. They are Sp2, Sp3, and Sp4 (29, 30) . These members of the same gene family show very similar structural features with highly conserved DNA binding domains and glutamine-rich activation domains (31) . We have previously identified Sp3 as being Band 1 in the mobility shift assays (10) . Sp3 binding to PII also appears to increase with glucose treatment. Hence, it is possible that Sp3, like Sp1, is being dephosphorylated by PP1 to bind to PII. However, when we transfected Sp3 in the Schneider cell line, which is devoid of Sp1 and related family members, we observed no activation of PII-CAT by Sp3 (10). Thus, Sp3 binding to PII may require other members of the family in order to have functional significance.
In this study, our goal has been to understand the mechanism of transactivation of PII by Sp1 under high glucose concentrations. We have shown that, while binding of Sp1 could be detected even in non-glucose-treated cells, it appeared to be stronger in the presence of glucose. Immunoblot studies carried out with polyclonal antibodies against Sp1 demonstrate that the amount of Sp1 in the cell remains unchanged even in the presence of glucose. Fractionation of glucose-treated 30A5 cell nuclear extracts revealed the presence of a 38 -42-kDa protein that was responsible for this enhanced binding activity of Sp1. In addition, this size protein was found to cross-react with a polyclonal antibody against PP1. Hence, the glucose-mediated FIG. 7 . Western blot analysis of PP1. Nuclear extracts from control and glucose-treated cells were run on a 10% SDS-polyacrylamide gel. After transfer to a nitrocellulose filter, the filter was blotted with a polyclonal antibody against PP1.
FIG. 8.
DNA mobility shift assay with anti-PP1-treated nuclear extracts. 30A5 nuclear extract was immunoprecipitated with anti-PP1 polyclonal antibody or with anti-PP1 and PP2A antibodies and then used in a mobility shift assay with labeled E-50-mer as the probe. The binding reactions were carried out without (lanes 2 and 3) or with PP1 antibody-treated (lanes 4 and 5) or with PP1 and PP2A antibodytreated (lanes 6 and 7) nuclear extracts. Lane 1 represents DNA alone. 5 ng of Sp1 was added to the nuclear extracts in lanes 3, 5, and 7. stimulation of PII appears to involve a modification event. As different types of stimuli that affect gene expression also lead to the activation of protein kinases, it is possible that the function of a transcription factor maybe regulated by phosphorylation. It has been shown that the DNA binding activity of nuclear factors can be modulated either positively or negatively by phosphorylation (15, 32, 33) . We next attempted to study if any of these mechanisms were involved in the Sp1-mediated regulation of the ACC gene. Before that, we observed an interesting phenomenon. We noticed that the addition of small amounts of Sp1 to nuclear extracts, which had been diluted severalfold, stimulated Sp1 binding to PII, even though the same amount of Sp1 could not bind DNA in a distinct band. The presence of Sp1 in the complex was confirmed by a supershift assay using antibodies against Sp1. Interestingly, this strong binding activity could be removed by the phosphatase inhibitor, OA (34) . On the other hand, the presence of the catalytic subunit of phosphatase 1 was able to recover the binding activity of Sp1 to that observed with nuclear extracts. The catalytic subunit of PP1 has a molecular mass of about 38 kDa, which is similar to that observed with the fraction of glucosetreated nuclear extract that can activate Sp1 binding to the E-50-mer. PP1 exists as different haloenzymes with a similar catalytic subunit associated with different regulatory compounds (35) . Thus, the glucose effect on PII could be mediated by the reversal of the negative regulation of Sp1 by phosphorylation. This mechanism would be similar to that observed in the case of the c-Myb protein. c-Myb is known to bind and activate promoters that contain sequences related to the sequence, CCGTTA. Phosphorylation of c-Myb by casein kinase II results in a large decrease in DNA binding activity, which is reversed by phosphatase treatment (32) . Another example is c-Jun, a component of the AP-1 complex. Again phosphorylation by GSK-3 has been shown to inhibit c-Jun/DNA binding (33) . Thus, inhibition of DNA binding by phosphorylation appears to be a common mechanism regulating several transcription factors. In most cases, phosphorylation occurs on sites either within or adjacent to the DNA binding domain. Further studies need to be carried out to determine which phosphorylation site(s) on Sp1 is important. We would then be able to understand better the mechanism of Sp1 mediated glucose activation of PII.
